Cargando…

Retinal Neurodegeneration and Visual Acuity Decline in Patients with Chronic Kidney Disease

INTRODUCTION: Chronic kidney disease (CKD) has been associated with accelerated retinal neurodegeneration. The purpose of this study is to evaluate the association between retinal neurodegeneration and the best-corrected visual acuity (BCVA) decline in patients with CKD. METHODS: Post hoc analysis o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Chi-Chin, Wu, I-Wen, Lee, Chin-Chan, Liu, Chun-Fu, Lin, Yu-Tze, Yeung, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011354/
https://www.ncbi.nlm.nih.gov/pubmed/36571674
http://dx.doi.org/10.1007/s40123-022-00635-3
_version_ 1784906373350293504
author Sun, Chi-Chin
Wu, I-Wen
Lee, Chin-Chan
Liu, Chun-Fu
Lin, Yu-Tze
Yeung, Ling
author_facet Sun, Chi-Chin
Wu, I-Wen
Lee, Chin-Chan
Liu, Chun-Fu
Lin, Yu-Tze
Yeung, Ling
author_sort Sun, Chi-Chin
collection PubMed
description INTRODUCTION: Chronic kidney disease (CKD) has been associated with accelerated retinal neurodegeneration. The purpose of this study is to evaluate the association between retinal neurodegeneration and the best-corrected visual acuity (BCVA) decline in patients with CKD. METHODS: Post hoc analysis of two prospective studies. Patients with CKD stage ≥ 3 were enrolled. Macular thickness, peripapillary retinal nerve fiber layer (pRNFL) thickness, and macular ganglion cell complex (GCC) thickness were measured by optical coherence tomography. Eyes were classified into three groups: Group 1, no GCC defect; Group 2, GCC defect confined to parafoveal area; and Group 3, GCC defects extending beyond the parafoveal area. Each group was matched for age, sex, axial length, lens status, and cataract grading. RESULTS: A total of 120 eyes (40 eyes in each group) from 120 patients (age 63.0 ± 10.3 years) were included. The logMAR BCVA was 0.076 ± 0.101, 0.100 ± 0.127, and 0.196 ± 0.191 in Group 1, 2, and 3, respectively. Group 3, but not Group 2, had a significantly worse BCVA than Group 1. In simple linear regression, parafoveal inner retinal thickness, pRNFL thickness, presence of pRNFL defect, GCC thickness, GCC global loss volume, GCC focal loss volume, and GCC defect extending beyond parafoveal area were associated with BCVA. Central subfield retinal thickness (CRT), parafoveal full retinal thickness, and parafoveal outer retinal thickness were not associated with BCVA. In backward stepwise linear regression, age and GCC defects extending beyond the parafoveal area were factors associated with BCVA. Moreover, GCC defect extending beyond parafoveal area was connected with worse BCVA in both phakic and pseudophakic subgroups. CONCLUSIONS: GCC defect extending beyond parafoveal area could be an independent biomarker associated with decreased BCVA in patients with CKD. However, macular thinning measured by CRT or parafoveal full retinal thickness might have low discriminative power in determining BCVA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-022-00635-3.
format Online
Article
Text
id pubmed-10011354
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-100113542023-03-15 Retinal Neurodegeneration and Visual Acuity Decline in Patients with Chronic Kidney Disease Sun, Chi-Chin Wu, I-Wen Lee, Chin-Chan Liu, Chun-Fu Lin, Yu-Tze Yeung, Ling Ophthalmol Ther Original Research INTRODUCTION: Chronic kidney disease (CKD) has been associated with accelerated retinal neurodegeneration. The purpose of this study is to evaluate the association between retinal neurodegeneration and the best-corrected visual acuity (BCVA) decline in patients with CKD. METHODS: Post hoc analysis of two prospective studies. Patients with CKD stage ≥ 3 were enrolled. Macular thickness, peripapillary retinal nerve fiber layer (pRNFL) thickness, and macular ganglion cell complex (GCC) thickness were measured by optical coherence tomography. Eyes were classified into three groups: Group 1, no GCC defect; Group 2, GCC defect confined to parafoveal area; and Group 3, GCC defects extending beyond the parafoveal area. Each group was matched for age, sex, axial length, lens status, and cataract grading. RESULTS: A total of 120 eyes (40 eyes in each group) from 120 patients (age 63.0 ± 10.3 years) were included. The logMAR BCVA was 0.076 ± 0.101, 0.100 ± 0.127, and 0.196 ± 0.191 in Group 1, 2, and 3, respectively. Group 3, but not Group 2, had a significantly worse BCVA than Group 1. In simple linear regression, parafoveal inner retinal thickness, pRNFL thickness, presence of pRNFL defect, GCC thickness, GCC global loss volume, GCC focal loss volume, and GCC defect extending beyond parafoveal area were associated with BCVA. Central subfield retinal thickness (CRT), parafoveal full retinal thickness, and parafoveal outer retinal thickness were not associated with BCVA. In backward stepwise linear regression, age and GCC defects extending beyond the parafoveal area were factors associated with BCVA. Moreover, GCC defect extending beyond parafoveal area was connected with worse BCVA in both phakic and pseudophakic subgroups. CONCLUSIONS: GCC defect extending beyond parafoveal area could be an independent biomarker associated with decreased BCVA in patients with CKD. However, macular thinning measured by CRT or parafoveal full retinal thickness might have low discriminative power in determining BCVA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-022-00635-3. Springer Healthcare 2022-12-26 2023-04 /pmc/articles/PMC10011354/ /pubmed/36571674 http://dx.doi.org/10.1007/s40123-022-00635-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Sun, Chi-Chin
Wu, I-Wen
Lee, Chin-Chan
Liu, Chun-Fu
Lin, Yu-Tze
Yeung, Ling
Retinal Neurodegeneration and Visual Acuity Decline in Patients with Chronic Kidney Disease
title Retinal Neurodegeneration and Visual Acuity Decline in Patients with Chronic Kidney Disease
title_full Retinal Neurodegeneration and Visual Acuity Decline in Patients with Chronic Kidney Disease
title_fullStr Retinal Neurodegeneration and Visual Acuity Decline in Patients with Chronic Kidney Disease
title_full_unstemmed Retinal Neurodegeneration and Visual Acuity Decline in Patients with Chronic Kidney Disease
title_short Retinal Neurodegeneration and Visual Acuity Decline in Patients with Chronic Kidney Disease
title_sort retinal neurodegeneration and visual acuity decline in patients with chronic kidney disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011354/
https://www.ncbi.nlm.nih.gov/pubmed/36571674
http://dx.doi.org/10.1007/s40123-022-00635-3
work_keys_str_mv AT sunchichin retinalneurodegenerationandvisualacuitydeclineinpatientswithchronickidneydisease
AT wuiwen retinalneurodegenerationandvisualacuitydeclineinpatientswithchronickidneydisease
AT leechinchan retinalneurodegenerationandvisualacuitydeclineinpatientswithchronickidneydisease
AT liuchunfu retinalneurodegenerationandvisualacuitydeclineinpatientswithchronickidneydisease
AT linyutze retinalneurodegenerationandvisualacuitydeclineinpatientswithchronickidneydisease
AT yeungling retinalneurodegenerationandvisualacuitydeclineinpatientswithchronickidneydisease